Charles Thornton

Adding a cell-penetrating peptide to a compound that reduces clump formation in cell nuclei increased its effectiveness in type 1 myotonic dystrophy research mice

posted on February 27, 2013 - 3:51pm
Scientists at the biopharmaceutical company Genzyme, working with mice, say they have modified and improved an existing experimental strategy to treat type 1 myotonic muscular dystrophy (MMD1, also known as DM1).
posted on July 1, 2012 - 3:00pm
QUEST Vol. 19, No. 3
The complex and multifaceted disease known as myotonic muscular dystrophy (MMD) — also known as dystrophia myotonia (DM) — was the subject of an In Focus report in the April-June 2012 Quest. Here, we delve into experimental strategies that may markedly improve the outlook for people with this disorder.
posted on July 1, 2012 - 3:00pm
QUEST Vol. 19, No. 3
Charles Thornton, a professor of neurology at the University of Rochester (N.Y.), has received MDA support for research in myotonic muscular dystrophy (MMD, also known as DM) and other neuromuscular diseases. He's currently developing antisense oligonucleotides and small molecules for MMD. Thornton also co-directs the MDA clinic and directs the MDA/ALS Center at the University of Rochester...
posted on October 1, 2009 - 3:52pm
QUEST Vol. 16, No. 4
Seattle resident Ken Lang (see “Like a Frog”) says he knew a disease that impairs swallowing and speaking was a possibility for him, because his father, uncle and grandmother had been affected by such a disorder.
posted on March 1, 2008 - 10:37pm
QUEST Vol. 15, No. 2
Myotonic dystrophy (MMD), a complex disease that results from an expanded and repeated section of DNA on either chromosome 19 (MMD1) or chromosome 3 (MMD2), has long posed a challenge to researchers because of its effects on multiple body systems, its varying degrees of severity and its complex molecular origins.